New Leukemia Treatment Using Transplant and Immune Therapy

Plain-English translation of NCT04746209 on ClinicalTrials.gov ↗ · Source last updated September 2021 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether a medication called , given after a specially prepared stem cell transplant, can help prevent leukemia from coming back in children and young adults with B-cell acute lymphoblastic leukemia (a type of blood cancer). The transplant uses cells that have been specially filtered to reduce harmful side effects, and the medication helps your immune system recognize and attack any remaining leukemia cells. The goal is to improve survival and quality of life for patients with high-risk or relapsed disease.

Right now, even after successful treatment, leukemia comes back in some patients, especially those with high-risk disease. This trial is testing whether adding this immune-boosting medication after transplant can reduce the chance of the cancer returning and help more patients stay healthy long-term.

Do you qualify?

You likely qualify if…

you have been diagnosed with B-cell acute lymphoblastic leukemia and have no detectable leukemia cells in your bone marrow by standard testing
you are in remission after a relapse, have very high-risk leukemia, or had remaining disease at the end of your initial treatment
you are 25 years old or younger at the time you join the study
you have an available donor (a family member or unrelated match) for a stem cell transplant
your heart, lungs, liver, and kidneys are working well enough for transplant, as confirmed by recent medical tests

You likely don't qualify if…

you have leukemia that has spread outside your bone marrow to other organs
you have had radiation to your brain or spine in the last 90 days
you have received other immune-boosting treatments (like CAR-T therapy) in the last 42 days
you are currently experiencing graft-versus-host disease (a complication from a previous transplant) or taking immune-suppressing medications for it
you are not able to use effective birth control during treatment and for 2 months after the medication ends

What participation looks like

If you qualify, you will first receive chemotherapy and possibly radiation (the type depends on test results showing whether tiny amounts of leukemia remain). Then you will receive the stem cell transplant using specially prepared donor cells. About 100 days after your transplant, assuming you are recovering well, you will begin a 28-day continuous infusion of the medication through a catheter (a small tube placed in a vein). You will need frequent hospital visits and blood tests during this time, and close monitoring will continue for months afterward to watch for side effects and signs of leukemia returning.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(1 site)

United States

Children's Hospital of Wisconsin, Milwaukee, Wisconsin